80708-25-4

Usage

Uses

Used in Pharmaceutical Research:
Pyrido[2,3-b]pyrazine-2,3-dione, 1,4-dihydro-4-methyl(9CI) is utilized as a research compound for its potential biological and therapeutic properties. Its unique structure and stability make it a promising candidate for the development of new drugs and therapeutic agents.
Used in Organic Chemistry Synthesis:
In the field of organic chemistry, Pyrido[2,3-b]pyrazine-2,3-dione, 1,4-dihydro-4-methyl(9CI) serves as a key intermediate in the synthesis of various organic compounds. Its stability and reactivity contribute to the creation of new molecules with specific functions and applications.
Used in Chemical Compound Libraries:
Pyrido[2,3-b]pyrazine-2,3-dione, 1,4-dihydro-4-methyl(9CI) is also used in the creation of chemical compound libraries, where it can be screened for potential interactions with biological targets, aiding in the discovery of new lead compounds for drug development.

Upstream product

• 5028-20-6 3-amino-2-methylaminopyridine 
• 95-92-1 oxalic acid diethyl ester 
• 79-37-8 oxalyl dichloride 
• 56291-51-1 2-amino-3-methylaminopyridine 
• 144-62-7 oxalic acid 
• 5470-18-8 2-Chloro-3-nitropyridine 
• 6153-56-6 oxalic acid dihydrate 
• 4093-88-3 2-(methylamino)-3-nitropyridine 
• 1480-87-1 2-fluoro-3-nitropyridine 

Relevant academic research and scientific papers

5,10-Dihydropyrido-pyrazolo-triazine compounds and application thereof

The invention relates to 5,10-dihydropyrido[2',3':5,6]pyrazolo[2,3-e][1,2,4]triazine compounds shown in general formula I, and their optical activators or racemates or their pharmaceutically acceptable salts, hydrates or solvates, wherein substituents R1,

Quinoxalinones

The invention features quinoxalinones, pharmaceutical compositions containing them and methods of using them to treat, for example, diabetes.

Synthesis and evaluation of 3-anilino-quinoxalinones as glycogen phosphorylase inhibitors

A series of 3-anilino-quinoxalinones has been identified as a new class of glycogen phosphorylase inhibitors. The lead compound 1 was identified through high throughput screening as well as through pharmacophore-based electronic screening. Modifications were made to the scaffold of 1 to produce novel analogues, some of which are 25 times more potent than the lead compound.

Tricyclic heterocyclic compounds as psychopharmaceuticals

New heterocyclic compounds having the general formula STR1 wherein STR2 CO2 R' or CONR'R", wherein R' and R" independently are C1-6 -alkyl, C3-7 -cycloalkyl or C1-6 -alkoxymethyl; --A-- is --C(=O)--NR'"--, --NR'"--C(=O)--, or STR3 wherein R'" is C1-6 -alkyl; X is C or N; and R4 is hydrogen, halogen, CN, C1-6 -alkyl, C1-6 -alkynyl, trimethylsilyl-C1-6 -alkynyl, aryloxy which may be substituted with halogen, aralkoxy, C3-7 -cycloalkoxy which may be substituted with one or more C1-6 -alkyl groups, or NR""R'"", wherein R"" and R'"" independently are C1-6 -alkoxy or together with the nitrogen atom form a 3-7 membered heterocyclic ring. The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, and nootropics.

Thiazoloquinoxalin-1,4-diones for treating allergy

New triazoloquinoxalin-1,4-diones are described as well as the use thereof as anti-allergenic agents.